Quantcast

Latest Fludarabine Stories

2010-02-18 15:49:00

SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL....

2009-12-05 14:00:00

The methods and outcomes for stem cell transplants are constantly improving as leading experts continue to investigate new approaches for reducing the serious adverse events associated with the procedure. Research presented today at the 51st Annual Meeting of the American Society of Hematology takes a closer look at complications of stem cell transplants, including veno-occlusive disease and graft-versus-host disease. "While stem cell transplant is one of the best treatment options we have...

2009-08-05 10:16:00

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market for these two products approximated $25 million in 2008. Sagent will begin marketing and shipping both products immediately. "We are very pleased to begin expanding our product line to include vital oncology...

d0280504311ba0aceafddc5c9d527b7e1
2009-05-28 06:30:00

U.S. drug regulators are carefully scrutinizing a new leukemia drug from pharmaceutical giant GlaxoSmithKline PLC and Genmab to determine whether the medication offers patients enough benefit to sanction its approval. Officials from the U.S. Food and Drug Administration stated that the exact degree of anti-cancer activity provided by the drug has proven "difficult to quantify" in patients with chronic lymphocytic leukemia (CLL), one of the more common varieties of adult blood cancer. "The...

2009-05-11 15:30:00

BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL. "We are extremely pleased to add Oforta to our existing oncology portfolio, and believe...

2009-01-30 10:00:00

Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Arzerra(TM) (ofatumumab) to treat patients whose chronic lymphocytic leukemia (CLL) is resistant (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal...

2008-12-10 07:30:00

Published in the Journal Blood for the American Society of Hematology Annual Meeting SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that American Society of Hematology (ASH) annual meeting abstracts in Blood (2008 112: Abstract 4205 & 2008 112: Abstract 4010) report that ONCONASE (ranpirnase) and R-Amphinase (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and acute myeloblastic leukemia (AML) cells alone as...

2008-12-09 07:00:00

Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who have poor prognostic indicators. These findings were presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco,...

2008-12-08 12:59:00

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today positive results from a pivotal trial pre-planned interim analysis of Arzerra(TM) (ofatumumab) in the treatment of refractory chronic lymphocytic leukemia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with...

2008-12-06 17:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse according to study results being presented in a press conference on Saturday, December 6, at 2:00 p.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research will be featured at the press conference that will...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related